BridgeBio Pharma, Inc. Revenue
BridgeBio Pharma, Inc. (BBIO) reported Revenue of $243.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-10
- BridgeBio Pharma, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $243.68M, a 120.39% increase year-over-year.
- BridgeBio Pharma, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $194.51M, a 66.78% increase year-over-year.
- BridgeBio Pharma, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $154.18M, a 2521.18% increase year-over-year.
- BridgeBio Pharma, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $120.70M, a 4318.01% increase year-over-year.
- BridgeBio Pharma, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $502.08M, a 126.26% increase from fiscal 2024.
- BridgeBio Pharma, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $221.90M, a 2285.27% increase from fiscal 2023.
- BridgeBio Pharma, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $9.30M, a 88.02% decline from fiscal 2022.
- BridgeBio Pharma, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $77.65M, a 11.38% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $243.68M 10-Q · filed 2026-08-10 | $438.19M 10-Q · filed 2026-08-10 | $592.37M derived: sum of 3 quarters · filed 2026-08-10 | $713.07M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $194.51M 10-Q · filed 2026-05-07 | $348.69M derived: sum of 2 quarters · filed 2026-05-07 | $469.39M derived: sum of 3 quarters · filed 2026-05-07 | $579.96M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $154.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $274.88M derived: sum of 2 quarters · filed 2026-02-24 | $385.44M derived: sum of 3 quarters · filed 2026-08-10 | $502.08M 10-K · filed 2026-02-24 |
| 2025-09-30 | $120.70M 10-Q · filed 2025-10-29 | $231.26M derived: sum of 2 quarters · filed 2026-08-10 | $347.90M 10-Q · filed 2025-10-29 | $353.78M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $110.56M 10-Q · filed 2026-08-10 | $227.20M 10-Q · filed 2026-08-10 | $233.08M derived: sum of 3 quarters · filed 2026-08-10 | $235.81M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $116.63M 10-Q · filed 2026-05-07 | $122.52M derived: sum of 2 quarters · filed 2026-05-07 | $125.25M derived: sum of 3 quarters · filed 2026-05-07 | $127.42M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $8.61M derived: sum of 2 quarters · filed 2026-02-24 | $10.78M derived: sum of 3 quarters · filed 2026-02-24 | $221.90M 10-K · filed 2026-02-24 |
| 2024-09-30 | $2.73M 10-Q · filed 2025-10-29 | $4.90M derived: sum of 2 quarters · filed 2025-10-29 | $216.02M 10-Q · filed 2025-10-29 | $217.76M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $2.17M 10-Q · filed 2025-08-05 | $213.29M 10-Q · filed 2025-08-05 | $215.03M derived: sum of 3 quarters · filed 2026-02-24 | $219.12M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $211.12M 10-Q · filed 2025-04-29 | $212.87M derived: sum of 2 quarters · filed 2026-02-24 | $216.96M derived: sum of 3 quarters · filed 2026-02-24 | $218.60M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.84M derived: sum of 2 quarters · filed 2026-02-24 | $7.48M derived: sum of 3 quarters · filed 2026-02-24 | $9.30M 10-K · filed 2026-02-24 |
| 2023-09-30 | $4.09M 10-Q · filed 2024-11-12 | $5.73M derived: sum of 2 quarters · filed 2024-11-12 | $7.56M 10-Q · filed 2024-11-12 | $9.43M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $1.64M 10-Q · filed 2024-08-01 | $3.47M 10-Q · filed 2024-08-01 | $5.34M derived: sum of 3 quarters · filed 2025-02-20 | $5.67M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $1.83M 10-Q · filed 2024-05-02 | $3.70M derived: sum of 2 quarters · filed 2025-02-20 | $4.03M derived: sum of 3 quarters · filed 2025-02-20 | $77.78M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $2.21M derived: sum of 2 quarters · filed 2025-02-20 | $75.95M derived: sum of 3 quarters · filed 2025-02-20 | $77.65M 10-K · filed 2025-02-20 |
| 2022-09-30 | $338.00K 10-Q · filed 2023-11-02 | $74.08M derived: sum of 2 quarters · filed 2023-11-02 | $75.78M 10-Q · filed 2023-11-02 | $88.66M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $73.75M 10-Q · filed 2023-08-03 | $75.44M 10-Q · filed 2023-08-03 | $88.33M derived: sum of 3 quarters · filed 2024-02-22 | $90.67M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $1.69M 10-Q · filed 2023-05-04 | $14.58M derived: sum of 2 quarters · filed 2024-02-22 | $16.92M derived: sum of 3 quarters · filed 2024-02-22 | $70.95M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $12.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $15.23M derived: sum of 2 quarters · filed 2024-02-22 | $69.25M derived: sum of 3 quarters · filed 2024-02-22 | $69.72M 10-K · filed 2024-02-22 |
| 2021-09-30 | $2.34M 10-Q · filed 2022-11-03 | $56.37M derived: sum of 2 quarters · filed 2022-11-03 | $56.83M 10-Q · filed 2022-11-03 | $56.95M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $54.02M 10-Q · filed 2022-08-04 | $54.49M 10-Q · filed 2022-08-04 | $54.61M derived: sum of 3 quarters · filed 2023-02-23 | $62.73M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $462.00K 10-Q · filed 2022-05-05 | $584.00K derived: sum of 2 quarters · filed 2023-02-23 | $8.71M derived: sum of 3 quarters · filed 2023-02-23 | |
| 2020-12-31 | $122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $8.25M derived: sum of 2 quarters · filed 2023-02-23 | $8.25M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $8.13M 10-Q · filed 2021-11-04 | $8.13M 10-Q · filed 2021-11-04 | ||
| 2019-12-31 | $13.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $40.56M derived: sum of 2 quarters · filed 2022-02-25 | $40.56M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $26.74M 10-Q · filed 2020-11-05 | $26.74M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |